MX2022006317A - Moduladores de canales iónicos. - Google Patents

Moduladores de canales iónicos.

Info

Publication number
MX2022006317A
MX2022006317A MX2022006317A MX2022006317A MX2022006317A MX 2022006317 A MX2022006317 A MX 2022006317A MX 2022006317 A MX2022006317 A MX 2022006317A MX 2022006317 A MX2022006317 A MX 2022006317A MX 2022006317 A MX2022006317 A MX 2022006317A
Authority
MX
Mexico
Prior art keywords
ion channel
disease
treating
channel modulators
condition relating
Prior art date
Application number
MX2022006317A
Other languages
English (en)
Inventor
Kiran Reddy
Botella Gabriel Martinez
Andrew Mark Griffin
Brian Edward Marron
Carlos Loya
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2022006317A publication Critical patent/MX2022006317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transmitters (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Amplifiers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere, en parte, a compuestos y composiciones de heteroarilo fusionado útiles para prevenir y/o tratar una enfermedad o afección relacionada con la función anómala de un canal de ion sodio sensible al voltaje, por ejemplo, corriente de sodio anormal tardía/constante. Los métodos para tratar una enfermedad o afección relacionada con la función anómala de un canal de ion sodio que incluye trastornos neurológicos (p. ej., síndrome de Dravet, epilepsia), dolor, y trastornos neuromusculares también se proporcionan en la presente descripción.
MX2022006317A 2019-11-26 2020-11-25 Moduladores de canales iónicos. MX2022006317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940500P 2019-11-26 2019-11-26
PCT/US2020/062179 WO2021108513A1 (en) 2019-11-26 2020-11-25 Ion channel modulators

Publications (1)

Publication Number Publication Date
MX2022006317A true MX2022006317A (es) 2022-06-22

Family

ID=76129716

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006317A MX2022006317A (es) 2019-11-26 2020-11-25 Moduladores de canales iónicos.

Country Status (15)

Country Link
US (1) US20230034917A1 (es)
EP (1) EP4065124A4 (es)
JP (1) JP2023503343A (es)
KR (1) KR20220119624A (es)
CN (1) CN114980899A (es)
AU (1) AU2020394421A1 (es)
BR (1) BR112022010186A2 (es)
CA (1) CA3162893A1 (es)
CL (1) CL2022001373A1 (es)
CO (1) CO2022008766A2 (es)
EC (1) ECSP22049654A (es)
IL (1) IL293256A (es)
MX (1) MX2022006317A (es)
PE (1) PE20221087A1 (es)
WO (1) WO2021108513A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
JP7105797B2 (ja) 2016-11-28 2022-07-25 プラクシス プレシジョン メディシンズ， インコーポレイテッド 化合物及びその使用方法
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
JP7359847B2 (ja) 2018-05-30 2023-10-11 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774715C (en) * 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN109790167B (zh) * 2016-09-02 2023-06-20 塞科里昂医疗股份有限公司 Sgc刺激剂
US11261188B2 (en) * 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
JP7105797B2 (ja) * 2016-11-28 2022-07-25 プラクシス プレシジョン メディシンズ， インコーポレイテッド 化合物及びその使用方法
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
JP7359847B2 (ja) * 2018-05-30 2023-10-11 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
US11279700B2 (en) * 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) * 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US20230348466A1 (en) * 2019-11-27 2023-11-02 Praxis Precision Medicines, Inc. Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
WO2023211852A1 (en) * 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Treatment of neurological disorders

Also Published As

Publication number Publication date
US20230034917A1 (en) 2023-02-02
ECSP22049654A (es) 2022-07-29
EP4065124A1 (en) 2022-10-05
CL2022001373A1 (es) 2023-03-10
PE20221087A1 (es) 2022-07-05
KR20220119624A (ko) 2022-08-30
BR112022010186A2 (pt) 2022-08-09
CN114980899A (zh) 2022-08-30
JP2023503343A (ja) 2023-01-27
AU2020394421A1 (en) 2022-06-09
IL293256A (en) 2022-07-01
EP4065124A4 (en) 2023-12-06
CA3162893A1 (en) 2021-06-03
CO2022008766A2 (es) 2022-07-19
WO2021108513A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2020012838A (es) Moduladores de los canales ionicos.
MX2021003634A (es) Moduladores de canales de iones.
MX2022006317A (es) Moduladores de canales iónicos.
MX2022006452A (es) Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos.
IN2006KO01346A (es)
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
PH12017500997A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
WO2003026479A3 (en) Methods of suppressing microglial activation
NZ742033A (en) Ion channel inhibitory compounds, pharmaceutical formulations and uses
MXPA03011083A (es) Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii.
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2009012188A (es) Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
MX353096B (es) Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
WO2002057215A3 (en) Sodium channel modulators
MX2022000492A (es) Formulaciones de moduladores de canal de calcio tipo t y metodos de uso de estos.
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX2022013595A (es) Metodos de uso de moduladores del canal de calcio tipo t.
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
PH12021551510A1 (en) Steroid compounds, uses and process for preparation therefor
AU2020264106A8 (en) Small molecule bromodomain inhibitors and uses thereof
EP1441724B8 (en) Methods of increasing endogenous testosterone levels
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
NZ742069A (en) Sodium channel blocker